<DOC>
	<DOCNO>NCT00245154</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . Cediranib maleate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving paclitaxel carboplatin together AZD2171 may kill tumor cell . It yet know whether give paclitaxel carboplatin together AZD2171 effective give paclitaxel carboplatin together placebo treat non-small cell lung cancer . PURPOSE : This randomized phase II/III trial study well give paclitaxel carboplatin together cediranib maleate work compare give paclitaxel carboplatin together placebo treat patient stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Paclitaxel Carboplatin With Without Cediranib Maleate Treating Patients With Stage III Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival patient stage IIIB IV non-small cell lung cancer treat paclitaxel carboplatin combination either cediranib maleate placebo . - Determine pharmacogenomics pharmacodynamic aspect regimens patient . ( Phase II ) - Compare overall survival patient treat regimen . ( Phase III ) Secondary - Compare objective tumor response rate patient treat regimen . - Determine time response response duration patient treat regimen . ( Phase III ) - Determine nature , severity , frequency toxic effect regimen , include hemorrhage hemoptysis , patient . - Correlate expression tissue marker ( diagnosis ) outcomes response patient treat regimen . ( Phase III ) - Compare quality life patient treat regimen . ( Phase III ) OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord gender , participate center , disease stage ( IIIB v IV ) , weight loss ( ≥ 5 % v &lt; 5 % ) , prior adjuvant chemotherapy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral cediranib maleate daily absence disease progression unacceptable toxicity . Patients also receive paclitaxel IV 3 hour carboplatin IV 30 minute day 1 . Treatment paclitaxel carboplatin repeat every 21 day 6-8 course absence disease progression unacceptable toxicity . - Arm II : Patients receive oral placebo daily absence disease progression unacceptable toxicity . Patients also receive paclitaxel carboplatin arm I . Quality life assess baseline , treatment course , completion study treatment , every 3 month thereafter . After completion study treatment , patient follow every 3 month . PROJECTED ACCRUAL : A total 750 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) , meet 1 follow stage criterion : Stage IIIB disease Patients without pleural effusion candidate combine modality treatment OR treat center combine modality treatment consider standard treatment eligible Stage IV disease Measurable disease ( phase II ) Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm xray , ultrasound , physical exam , conventional CT scan OR ≥ 10 mm spiral CT scan Measurable lesion must outside previous radiotherapy field sole site disease , unless disease progression document No significant central thoracic lesion appreciable cavitation Measurable nonmeasurable disease ( phase III ) No necrotic hemorrhagic tumor metastases No untreated brain meningeal metastasis CT scan require rule disease unless clinical suspicion CNS disease Patients previously treat stable brain metastasis ( radiography clinical exam ) eligible provide asymptomatic require corticosteroid PATIENT CHARACTERISTICS : Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 No overt bleeding ( i.e. , ≥ 30 mL/episode ) within past 3 month Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 2 time ULN ( &lt; 5 time ULN liver metastasis present ) Renal Creatinine clearance ≥ 50 mL/min Proteinuria ≤ grade 1 Cardiovascular Mean QTc ≤ 470 msec ( Bazett 's correction ) ECG No unstable angina No congestive heart failure No myocardial infarction within past year No cardiac ventricular arrhythmia require medication No history 2nd 3rddegree atrioventricular conduction defect No untreated uncontrolled cardiovascular condition No symptomatic cardiac dysfunction No uncontrolled hypertension ( i.e. , rest blood pressure ≥ 150/100 mm Hg despite antihypertensive therapy ) No history labile hypertension No history poor compliance antihypertensive medication No history familial longQT syndrome Pulmonary No clinically relevant hemoptysis ( i.e. , ≥ 5 mL fresh blood ) within past 4 week Flecks blood sputum allow Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective ( double method female ; barrier method male ) contraception Able willing participate quality life assessment No peripheral neuropathy &gt; grade 1 No prior allergic reaction drug contain Cremophor EL® No active uncontrolled infection No serious illness medical condition would preclude study compliance No inflammatory bowel disease ( e.g. , Crohn 's disease ulcerative colitis ) No malignancy within past 5 year except basal cell squamous cell skin cancer situ cancer PRIOR CONCURRENT THERAPY : Biologic therapy At least 14 day since prior epidermal growth factor receptorinhibitor therapy ( e.g. , tyrosine kinase inhibitor , monoclonal antibody , vaccine , agent ) No prior antiangiogenesis therapy , include follow : Bevacizumab Cediranib maleate AZD6474 PTK787/ZK222584 ( PTK/ZK ) Sunitinib malate Concurrent epoetin alfa allow Chemotherapy At least 12 month since prior adjuvant chemotherapy Combined chemotherapy radiotherapy regimens locally advanced stage IIIB disease consider adjuvant therapy allow No prior chemotherapy metastatic recurrent NSCLC Endocrine therapy See Disease Characteristics At least 1 week since prior steroid Radiotherapy See Disease Characteristics At least 21 day since prior radiotherapy except lowdose nonmyelosuppressive radiotherapy approval Concurrent palliative radiotherapy allow approval Surgery At least 14 day since prior major surgery Other Recovered prior therapy Prior treatment cyclooxygenase2 inhibitor allow Concurrent prophylactic anticoagulation ( e.g. , warfarin ) allow provided requirement INR meet No potent inhibitor CYP3A4 2C8 , include follow drug : Amiodarone hydrochloride Clarithromycin Citalopram hydrobromide Erythromycin Omeprazole Simvastatin Atorvastatin Lovastatin Montelukast sodium Verapamil hydrochloride Ketoconazole Miconazole Indinovir antivrails Diltiazem No concurrent experimental drug anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>